Core Viewpoint - The Chinese medical hydrogel industry is projected to reach a market size of approximately 650 million yuan in 2024, reflecting a year-on-year growth of 4.84%, driven by the gradual application of advanced medical technologies in key healthcare areas [1][8]. Industry Overview - Medical hydrogels are three-dimensional network structures formed from hydrophilic polymers, characterized by high water absorption, biocompatibility, and the ability to maintain a moist environment. They can be modified to possess specific properties such as self-healing and environmental responsiveness [2][4]. Market Size - The global medical hydrogel market is expected to reach approximately 2.292 billion USD in 2024, with a year-on-year growth of 2.79%. The increasing demand for chronic wound management, particularly among the elderly population, is driving the application of medical hydrogels in wound care, drug delivery, and tissue engineering [8][9]. Key Enterprises - The industry is characterized by a competitive landscape where leading companies dominate, and specialized firms focus on niche areas. Changchun Jiyuan Biological, a leader in the high-end hydrogel market, offers a range of products including wound dressings and eye therapy patches, while Huayang Medical specializes in silicone gel and hemostatic materials [9][10][12]. Industry Development Trends 1. **Technological Innovation**: The future of the medical hydrogel industry in China will focus on the integration of smart responsive materials and bioprinting technology. For instance, the innovative cervical cancer radiotherapy protective hydrogel by Ruining Bio has gained clinical attention [12][13]. 2. **Market Demand Expansion**: The growth of the medical hydrogel market is primarily driven by the aging population and the expansion of regenerative medicine applications. The demand for moist healing dressings is expected to rise significantly due to the increasing prevalence of chronic wounds [13][14]. 3. **Regulatory Environment and Competition**: Stricter industry regulations and local technological advancements are shaping a competitive landscape. Domestic companies are leveraging cost advantages to replace international brands, while also expanding into overseas markets [14][15].

Core Viewpoint - The article highlights the ambition of Suzhou Nopu Regenerative Medicine Co., Ltd. to develop a biological 3D printing platform aimed at creating health solutions for humanity, allowing for the rapid production of body parts using a patient's own cells and biomaterials [2]. Group 1: Company Overview - Nopu Regenerative has established the first biological printing medical device production workshop in China and developed the OPUS biological printing technology platform, filling a gap in clinical applicability in the country [2]. - The company has obtained over 40 national patents and more than 10 software copyrights, participating in the establishment of multiple industry standards [2]. Group 2: Market Demand and Vision - The founder, Yang Xi, identified a significant demand for organ and tissue regeneration, noting that over 6 million people in China suffer from bone defects annually, with around 3 million needing skin repair and 4 million suffering from blindness [4]. - The company aims to create a platform that serves global health needs, emphasizing the importance of clinical application and commercialization in its technology development [4]. Group 3: Unique Business Model - Nopu Regenerative's business model focuses on creating a cross-disciplinary ecosystem by collaborating with top medical teams, establishing commercial barriers through professional recognition and reputation [5]. - The company emphasizes the development of human tissue substitutes to address supply shortages in organ transplantation and tissue engineering [5]. Group 4: Successful Collaborations - Nopu Regenerative has successfully collaborated with several top medical institutions, including Beijing Jishuitan Hospital and Shanghai Jiaotong University, to create customized artificial bones for patients, which has garnered significant attention in the professional field [6]. Group 5: Entrepreneurial Spirit - The founder emphasizes the importance of passion and commitment in entrepreneurship, fostering a culture of responsibility and innovation within the company [7]. - Yang Xi believes that gender does not determine success in business, and she aims to inspire more women to pursue their dreams in the biomedical field [7].